PLUS THERAPEUTICS, INC. Logo

PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):
US23283K2042 (+1 more)
LEI:
Country:
United States of America
Address:
4200 MARATHON BLVD., 78756 AUSTIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel
SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea
096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan
4548
SELLAS Life Sciences Group, Inc. Logo
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
United States of America
SLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.